Fortrea Holdings Under Investigation by Kahn Swick & Foti Amid Disappointing Financials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2026
0mins
Should l Buy FTRE?
Source: PRnewswire
- Disappointing Financials: Fortrea Holdings reported that its Q4 and full-year 2024 results missed previously announced guidance for revenue and adjusted EBITDA, indicating lower-than-expected profitability post-spin-off, which could undermine shareholder confidence.
- Legal Action Risks: The company and its executives are facing a securities class action lawsuit for failing to disclose material information, which could lead to significant financial liabilities and exacerbate market concerns about its future prospects.
- Transition Services Agreements: Fortrea's agreements with Labcorp require payments for transitional services, and failure to effectively utilize these services may impose additional financial burdens, negatively impacting cash flow and operational efficiency.
- Investigation Focus: Kahn Swick & Foti is investigating whether Fortrea's executives breached their fiduciary duties to shareholders, and if violations are confirmed, it could lead to broader legal repercussions affecting the company's governance structure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FTRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FTRE
Wall Street analysts forecast FTRE stock price to rise
8 Analyst Rating
3 Buy
4 Hold
1 Sell
Hold
Current: 10.480
Low
7.00
Averages
15.33
High
25.00
Current: 10.480
Low
7.00
Averages
15.33
High
25.00
About FTRE
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Fortrea Holdings Inc. Reports Q4 2025 Earnings Insights
- Solid Financial Performance: Fortrea Holdings reported Q4 2025 revenue of $660.5 million, a 5.2% year-over-year decline, yet achieved full-year revenue of $2.7234 billion, reflecting resilience in a challenging environment.
- Significant Cost Savings: The company delivered approximately $153 million in gross savings and $93 million in net savings for 2025, exceeding targets and indicating effective cost optimization that is expected to support future profitability.
- Leadership Changes: The appointments of Aggie Gallagher as General Counsel and Dr. Scott Dove to lead Clinical Pharmacology aim to enhance strategic execution and market competitiveness, highlighting the company's focus on strengthening its executive team.
- Cautiously Optimistic Outlook: Revenue for 2026 is projected between $2.55 billion and $2.65 billion, with management acknowledging ongoing FSP headwinds and anticipated revenue declines, yet expressing cautious optimism about market recovery and continued cost-saving initiatives.
See More
FORTREA HOLDINGS STOCK FALLS 2.3% AS COMPANY PREDICTS FY26 REVENUE BELOW EXPECTATIONS
Stock Performance: Fortrea Holdings' shares have decreased by 2.3%.
Revenue Forecast: The decline follows forecasts indicating that FY26 revenue will fall below expectations.
See More
Fortrea Holdings Q4 Earnings Miss Expectations
- Earnings Report Shortfall: Fortrea Holdings reported a Q4 non-GAAP EPS of $0.09, missing expectations by $0.07, indicating pressure on profitability that may affect investor confidence.
- Revenue Decline: The company’s Q4 revenue of $660.5 million represents a 5.2% year-over-year decline, failing to meet expectations and reflecting weak market demand that could pressure future performance.
- 2026 Performance Outlook: Fortrea targets revenues between $2.55 billion and $2.65 billion for 2026, with adjusted EBITDA projected between $190 million and $220 million, indicating a cautious outlook on future growth.
- Impact of Management Changes: The upgrade by Evercore ISI highlights management changes that may influence the company's strategic direction and market confidence, particularly against the backdrop of evolving drug approval policies.
See More
Fortrea Holdings to Announce Earnings Tomorrow
- Earnings Announcement: Fortrea Holdings is set to announce its earnings tomorrow, with market expectations indicating a 4.3% year-over-year revenue decline, reflecting increased challenges compared to a 1.8% decline in the same quarter last year.
- Performance Review: Last quarter, Fortrea reported revenues of $701.3 million, a 3.9% year-over-year increase that exceeded analyst expectations, and its full-year revenue guidance also surpassed market forecasts, indicating strong performance in the previous quarter.
- Market Reaction: Despite Fortrea's strong quarterly performance, the company has missed Wall Street's revenue estimates multiple times over the past two years, leading to a 36.8% decline in its stock price over the past month, while peers like Medpace and UFP Technologies have shown relative stability.
- Analyst Expectations: Analysts have generally reaffirmed their estimates over the past 30 days, with an average price target of $16.44 compared to the current share price of $10.98, indicating cautious optimism regarding Fortrea's future performance.
See More
Fortrea Holdings Under Investigation by Kahn Swick & Foti Amid Disappointing Financials
- Disappointing Financials: Fortrea Holdings reported that its Q4 and full-year 2024 results missed previously announced guidance for revenue and adjusted EBITDA, indicating lower-than-expected profitability post-spin-off, which could undermine shareholder confidence.
- Legal Action Risks: The company and its executives are facing a securities class action lawsuit for failing to disclose material information, which could lead to significant financial liabilities and exacerbate market concerns about its future prospects.
- Transition Services Agreements: Fortrea's agreements with Labcorp require payments for transitional services, and failure to effectively utilize these services may impose additional financial burdens, negatively impacting cash flow and operational efficiency.
- Investigation Focus: Kahn Swick & Foti is investigating whether Fortrea's executives breached their fiduciary duties to shareholders, and if violations are confirmed, it could lead to broader legal repercussions affecting the company's governance structure.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Fortrea Holdings Inc. Reports Q4 2025 Earnings Insights
- Solid Financial Performance: Fortrea Holdings reported Q4 2025 revenue of $660.5 million, a 5.2% year-over-year decline, yet achieved full-year revenue of $2.7234 billion, reflecting resilience in a challenging environment.
- Significant Cost Savings: The company delivered approximately $153 million in gross savings and $93 million in net savings for 2025, exceeding targets and indicating effective cost optimization that is expected to support future profitability.
- Leadership Changes: The appointments of Aggie Gallagher as General Counsel and Dr. Scott Dove to lead Clinical Pharmacology aim to enhance strategic execution and market competitiveness, highlighting the company's focus on strengthening its executive team.
- Cautiously Optimistic Outlook: Revenue for 2026 is projected between $2.55 billion and $2.65 billion, with management acknowledging ongoing FSP headwinds and anticipated revenue declines, yet expressing cautious optimism about market recovery and continued cost-saving initiatives.
See More
FORTREA HOLDINGS STOCK FALLS 2.3% AS COMPANY PREDICTS FY26 REVENUE BELOW EXPECTATIONS
Stock Performance: Fortrea Holdings' shares have decreased by 2.3%.
Revenue Forecast: The decline follows forecasts indicating that FY26 revenue will fall below expectations.
See More
Fortrea Holdings Q4 Earnings Miss Expectations
- Earnings Report Shortfall: Fortrea Holdings reported a Q4 non-GAAP EPS of $0.09, missing expectations by $0.07, indicating pressure on profitability that may affect investor confidence.
- Revenue Decline: The company’s Q4 revenue of $660.5 million represents a 5.2% year-over-year decline, failing to meet expectations and reflecting weak market demand that could pressure future performance.
- 2026 Performance Outlook: Fortrea targets revenues between $2.55 billion and $2.65 billion for 2026, with adjusted EBITDA projected between $190 million and $220 million, indicating a cautious outlook on future growth.
- Impact of Management Changes: The upgrade by Evercore ISI highlights management changes that may influence the company's strategic direction and market confidence, particularly against the backdrop of evolving drug approval policies.
See More
Fortrea Holdings to Announce Earnings Tomorrow
- Earnings Announcement: Fortrea Holdings is set to announce its earnings tomorrow, with market expectations indicating a 4.3% year-over-year revenue decline, reflecting increased challenges compared to a 1.8% decline in the same quarter last year.
- Performance Review: Last quarter, Fortrea reported revenues of $701.3 million, a 3.9% year-over-year increase that exceeded analyst expectations, and its full-year revenue guidance also surpassed market forecasts, indicating strong performance in the previous quarter.
- Market Reaction: Despite Fortrea's strong quarterly performance, the company has missed Wall Street's revenue estimates multiple times over the past two years, leading to a 36.8% decline in its stock price over the past month, while peers like Medpace and UFP Technologies have shown relative stability.
- Analyst Expectations: Analysts have generally reaffirmed their estimates over the past 30 days, with an average price target of $16.44 compared to the current share price of $10.98, indicating cautious optimism regarding Fortrea's future performance.
See More
Fortrea Holdings Under Investigation by Kahn Swick & Foti Amid Disappointing Financials
- Disappointing Financials: Fortrea Holdings reported that its Q4 and full-year 2024 results missed previously announced guidance for revenue and adjusted EBITDA, indicating lower-than-expected profitability post-spin-off, which could undermine shareholder confidence.
- Legal Action Risks: The company and its executives are facing a securities class action lawsuit for failing to disclose material information, which could lead to significant financial liabilities and exacerbate market concerns about its future prospects.
- Transition Services Agreements: Fortrea's agreements with Labcorp require payments for transitional services, and failure to effectively utilize these services may impose additional financial burdens, negatively impacting cash flow and operational efficiency.
- Investigation Focus: Kahn Swick & Foti is investigating whether Fortrea's executives breached their fiduciary duties to shareholders, and if violations are confirmed, it could lead to broader legal repercussions affecting the company's governance structure.
See More
